Thursday, December 01, 2016 9:18:07 AM
NEW YORK, NY--(Marketwired - December 01, 2016) - PharmaCyte Biotech (PMCB) is now one step closer to enrolling patients in a pivotal clinic trial in advanced, inoperable pancreatic cancer after the FDA granted its request for a pre-IND (Investigational New Drug) meeting. A host of oncologists, clinicians and scientists that represent PharmaCyte will now sit down with the U.S. regulatory agency to gain valuable insight that will assist them in filing an Investigational New Drug application -- the final step before patients can be enrolled in a clinical trial.
With PharmaCyte and a team of world-renowned oncologists that includes leading pancreatic cancer expert Dr. Daniel Von Hoff from Translational Drug Development (TD2), Dr. Manuel Hidalgo from Harvard Medical School, and Dr. Matthias Löhr from the Karolinska Institute in Stockholm, Sweden, set to begin a clinical trial in the U.S. and Europe, the FDA's IND process is vital to getting there.
After the IND process runs its course, shareholders should be prepared for what a planned 6-month "hard stop" in the clinical trial could bring in the way of data to the industry. If past performance in earlier clinical trials is any indication, PharmaCyte may be a short time away from what could be a very powerful story for patients with advanced, inoperable pancreatic cancer.
PharmaCyte Could Apply for Breakthrough Therapy Designation
The review of data at the 6-month hard stop could very well lead to PharmaCyte's therapy being given the Breakthrough Therapy Designation by the FDA.
A breakthrough therapy is a drug/therapy:
Intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition, and
Preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
According to the FDA, if a drug/therapy is designated as breakthrough therapy, the FDA will speed up the development and review of the drug/therapy.
PharmaCyte's pancreatic cancer therapy has already received the Orphan Drug Designation from both the FDA and the European Medicines Agency (EMA), so if the company can repeat the data from earlier clinical trials, there is a very good chance that PharmaCyte could earn the breakthrough therapy designation from the FDA as well.
There are two areas specifically that could lead to this designation: (1) quality of life and (2) how well PharmaCyte's therapy can shrink inoperable tumors so that they may become operable. In earlier trials, the company's treatment did improve the quality of life and it did show the ability to shrink a pancreatic tumor.
PharmaCyte Addressing an Unmet Medical Need
PharmaCyte has recognized that there is currently an unmet medical need for patients with locally advanced pancreatic cancer (LAPC) that no longer receive any benefit from using the standard of care for the disease (the combination of Abraxane® plus gemcitabine) after 4-6 months of treatment. PharmaCyte expects that its therapy can meet that unmet medical need. The company will enroll those patients whose cancer no longer responds after 4-6 months of treatment using the current gold standard.
In PharmaCyte's clinical trial, about 84 patients with LAPC will be randomly placed into two equal groups.
Group 1 will receive just the chemotherapy drug gemcitabine
Group 2 will receive PharmaCyte's pancreatic cancer therapy
Those who are familiar with PharmaCyte are also familiar with the impressive data from earlier clinical trials where PharmaCyte's pancreatic cancer therapy dramatically outperformed historical data from gemcitabine. In this upcoming clinical trial the company's therapy will go head-to-head with gemcitabine.
PharmaCyte's pancreatic cancer therapy uses the company's signature live-cell encapsulation technology, Cell-in-a-Box® plus low doses of the FDA-approved chemotherapy drug ifosfamide.
The pinhead-sized, porous capsules (Cell-in-a-Box®), which are placed as close to the pancreatic tumor as possible, are filled with thousands of genetically modified cells that act as a type of "artificial liver" in the sense that these genetically modified cells (about 10,000 cells per capsule) are capable of converting ifosfamide from its normally inactive form into its active cancer-killing form -- just as the enzyme system in a patient's liver would normally do.
By moving the conversion site of the chemotherapy drug (from the liver to the Cell-in-a-Box® capsules) closer to the pancreatic tumor, PharmaCyte's therapy can use a lower dose (1/3 the normal dose) of the chemotherapy drug. The benefit to using a lower dose is that it eliminates the side effects normally seen in patients undergoing chemotherapy, and it is the elimination of these side effects that improved the patient's quality of life in earlier clinical trials.
http://finance.yahoo.com/news/pharmacyte-biotech-moves-closer-enrolling-140000586.html
Recent PMCB News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/13/2024 08:37:40 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 07/29/2024 08:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:59:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:35 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:05:04 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/30/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:40:20 PM
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease • Business Wire • 05/21/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM